Back to Peptides
LongevityLow Risk

Vesugen

Also known as: Lys-Glu-Asp, Vascular bioregulator, Khavinson vascular peptide

Half-life:
Unknown

Administration Routes

subcutaneous injectionoral
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Tripeptide bioregulator targeting vascular endothelium; normalizes gene expression in smooth muscle and endothelial cells; reduces lipid accumulation in vessel walls

A Khavinson vascular peptide bioregulator that supports endothelial integrity and cardiovascular health. Studied for atherosclerosis prevention and vascular aging.

Primary Research Areas

  • vascular repair
  • endothelial function
  • cardiovascular anti-aging
  • atherosclerosis reduction

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Russian vascular peptide bioregulator (Lys-Glu-Asp) from Khavinson Institute. Developed for vascular endothelium health. Not FDA-approved. Not on any FDA list. Research chemical.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Vesugen

No active associated providers listed yet.